Stout Advises Clinique de Maisonneuve on a Significant Stake Sale

May 03, 2021

Stout is pleased to announce that its client, Clinique de Maisonneuve (CM), has sold a significant stake to Impact Healthcare, a company owned by Après-demain (Debiopharm). Stout served as exclusive financial advisor to CM in connection with this transaction.

Based in Geneva, CM was created in 2013 to support post-acute patients and help them regain their autonomy. Thanks to advanced programs, equipment, and techniques, CM has developed customized rehabilitation care with a wide range of services. CM recently opened a 665-square-meter outpatient rehabilitation center, complementing its first clinic that comprises 44 rooms dedicated to inpatient rehabilitation.

Through this investment, Impact Healthcare is pursuing its strategy of providing a platform for sharing and pooling resources, networks, and coordination of the patient care journey.

“We were very pleased with the transaction,” said CM Board Member Corinne Chapel. “Clinique de Maisonneuve will benefit from the synergy with Impact Healthcare to provide best-in-class patient care. The Stout team guided the whole process in a very professional manner.”

“We are very satisfied with the results and delighted to support Clinique de Maisonneuve in such an important milestone in its development,” said Managing Director and Head of Stout’s Lausanne, Switzerland office, Christophe Lapaque, who led the Stout deal team.

See more information on our Investment Banking services.